UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target raised by UBS Group from $28.00 to $30.00 in a research note published on Thursday,Benzinga reports. UBS Group currently ...

Below is Validea's guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow, TEVA rates highest using our Twin Momentum Investor model based ...

UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...

The FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa. Pharmaceutical companies brace for the upcoming Trump administration. Teva ...

Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the world.

After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to unlock ... to pick up $2.5 billion in sales by 2027, CEO Richard Francis ...

These 15 Sandals Are Actually Comfortable Teva street style on sale, Three of the Best Ways to Style Tevas for Fall and Still Look on sale, 20 Street Style Trends to try for Summer Say Yes Street ...

Oil and gas company TotalEnergies and offshore drilling contractor Vantage Drilling International have established a joint venture (JV) entity, TEVA Ship Charter. The formation of the JV follows a ...

Walmart is slashing prices on best-selling tech gadgets with a massive sale on TVs, laptops, and Apple devices. January is a perfect time to score a clearance deal on last year's best-selling tech ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...